SCHEMBL197003

SCHEMBL197003

O=C(Nc1ccc(Cl)cc1)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
ALDH1A1 P00352 2/20 0.73
POLB P06746 2/20 0.73
HPGD P15428 1/20 0.73
PTPN1 P18031 2/20 0.71
NPC1 O15118 9/20 0.70
RAB9A P51151 9/20 0.70
EPHX1 P07099 1/20 0.70
NPSR1 Q6W5P4 1/20 0.70
SIRT1 Q96EB6 1/20 0.69
KDM4E B2RXH2 1/20 0.69
SMO Q99835 1/20 0.69
PTGS2 P35354 1/20 0.68
MAPK1 P28482 1/20 0.68
MAPT P10636 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
TDP1 Q9NUW8 1/20 0.65
CACNA1B Q00975 1/20 0.65
APBA1 Q02410 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL30758572 0.98 MEN1 (0.71) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL11550249 0.94 MEN1 (0.68) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL2117869 0.92 PTPN1 (0.71) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL9767723 0.90 NPC1 (0.76) MEN1KMT2APOLBPTPN1NPC1
SCHEMBL611657 0.90 NPC1 (0.76) MEN1KMT2APOLBPTPN1NPC1
SCHEMBL10939703 0.90 NPC1 (0.76) MEN1KMT2APOLBPTPN1NPC1
SCHEMBL126415 0.89 PTPN1 (0.87) MEN1KMT2APOLBPTPN1NPC1
SCHEMBL19501649 0.89 SIRT1 (0.77) MEN1KMT2AALDH1A1POLBHPGD
SCHEMBL14715824 0.87 NPC1 (0.88) MEN1KMT2APOLBHPGDPTPN1
SCHEMBL18103163 0.87 NPC1 (0.88) MEN1KMT2APOLBHPGDPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109232411-A A method of preparing boscalid 广东广康生化科技股份有限公司 2019-01-18 CN claimed
EP-1129075-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS Novartis AG (CH) 2001-09-05 EP claimed
WO-2000027820-A1 N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2000-05-18 WO claimed
EP-0273444-A2 Use of carboxamide compounds for the preparation of a medicament for treating hyperlipidemia OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1988-07-06 EP claimed
US-20260125340-A1 METHOD FOR PREPARING AMIDES FROM ESTERS BASF SE (DE) 2026-05-07 US disclosed
EP-4598900-A1 METHOD FOR PREPARING AMIDES FROM ESTERS BASF SE (DE) 2025-08-13 EP disclosed
CN-119998260-A Process for preparing amides from esters 巴斯夫欧洲公司 2025-05-13 CN disclosed
CN-118048636-B Electrocatalytic synthesis method for N-aryl amide 平顶山学院 2024-09-13 CN disclosed
CN-118420484-B Method for preparing amide compounds 四川大学 2024-08-30 CN disclosed
CN-118420484-A Method for preparing amide compounds 四川大学 2024-08-02 CN disclosed
CN-118048636-A Electrocatalytic synthesis method for N-aryl amide 平顶山学院 2024-05-17 CN disclosed
WO-2024074641-A1 METHOD FOR PREPARING AMIDES FROM ESTERS BASF SE (DE) 2024-04-11 WO disclosed
US-5514740-A SHEET OR FILM HAVING CUPRIC SULFIDE DISPERSED THEREIN DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1996-05-07 US disclosed
EP-0273444-A2 Use of carboxamide compounds for the preparation of a medicament for treating hyperlipidemia OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1988-07-06 EP disclosed
US-4499167-A Photoconductive compositions comprising an organic photoconductor and an amide compound and electro-photographic light-sensitive materials using the compositions FUJI PHOTO FILM CO., LTD. (JP) 1985-02-12 US disclosed
US-4487781-A HEAT RESISTANCE; PHOTOSTABILITY SANKYO COMPANY LIMITED (JP) 1984-12-11 US disclosed
EP-0057058-B1 A METHOD OF PRESERVING ORGANIC MATERIALS FROM FUNGAL ATTACK AND A COMPOSITION FOR USE IN SUCH A METHOD SANKYO COMPANY LIMITED (JP) 1984-04-11 EP disclosed
US-4421766-A 3-HALO-2,3-DIIODOACRYLIC ACID OR ESTER SANKYO CO., LTD. (JP) 1983-12-20 US disclosed
EP-0057058-A1 A method of preserving organic materials from fungal attack and a composition for use in such a method SANKYO COMPANY LIMITED (JP) 1982-08-04 EP disclosed
US-4093648-A ANTIANAPHYLACTIC AGENTS RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125340-A1 METHOD FOR PREPARING AMIDES FROM ESTERS CBR1, CBR3, SCO2 MEN1 2007/4885KMT2A 1928/4885ALDH1A1 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.